|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02196 FOSUN PHARMA
Nominal 
14.000 -0.540 (-3.714%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 41,248,505 | -5.850% | 43,811,385 | 38,864,174 | 30,163,260 | 28,389,277 |
| Cost of Sales | (21,595,309) | -6.795% | (23,169,690) | (20,229,785) | (13,733,529) | (11,543,421) |
| Gross Profit | 19,653,196 | -4.789% | 20,641,695 | 18,634,389 | 16,429,731 | 16,845,856 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (131,927) | 101.819% | (65,369) | (74,016) | (104,836) | (97,114) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 2,184,849 | 19.056% | 1,835,146 | 1,789,137 | 1,580,335 | 1,431,414 | |
| Profit / (Loss) before Taxation | 3,276,908 | -28.460% | 4,580,552 | 6,042,670 | 4,677,846 | 4,525,753 | |
| Taxation | (369,504) | -41.060% | (626,918) | (1,066,401) | (737,865) | (782,231) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (508,798) | 134.838% | (216,659) | (247,558) | (277,168) | (421,904) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,398,606 | -35.814% | 3,736,975 | 4,728,711 | 3,662,813 | 3,321,618 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 961,186 | 41.108% | 681,172 | 588,755 | 681,343 | 888,042 |
| Depreciation & Amortisation | 3,202,753 | 28.298% | 2,496,331 | 1,948,448 | 1,728,137 | 1,520,479 |
| Directors' Emoluments | 48,086 | -3.841% | 50,007 | 39,627 | 31,033 | 26,864 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 90.000 | -37.063% | 143.000 | 185.000 | 143.000 | 130.000 |
| DPS (cts) | 27.000 | -- | 42.000 | 56.000 | 43.000 | 39.000 |
| Dividend Payout Ratio (%) | 30.000% | -- | 29.371% | 30.270% | 30.070% | 30.000% |
| Cash flow per share ($) | 1.279 | -- | 1.618 | 1.536 | 1.007 | 1.257 |
| NBV per share ($) | 17.081 | -- | 16.665 | 15.271 | 14.413 | 12.420 |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,224,799 |
| %Change | -31.332% |
| EPS / (LPS) | RMB 0.460 |
| NBV Per Share (¥) | RMB 17.561 |